Find a Clinical Trial for WM

Filters

Phase

Recruitment Status

Region

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Testing a new treatment to understand it’s efficacy and the best dose for patients

Expected to end: 31/03/2028

A Long-term Extension Study of PCI-32765 (Ibrutinib) (CAN3001)

Studying the long-term effects of Ibrutinib in people who were on previous trials for the drug that have now closed

Expected to end: 29/01/2027

A study looking at stem cell outcomes (BOOST)

Understanding how we can make stem cell transplants more successful

Expected to end: 31/12/2025

A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

A first-in-human study to test the safety and efficacy of a new targeted treatment

Expected to end: 31/05/2025

A study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma

An early phase study of the efficacy and safety of a new drug

Expected to end: 08/01/2026

A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies

The first trial in humans for a new type of BTK degrader

Expected to end: 01/01/2028

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Understanding the best dosage for a BTK inhibitor called Pirtobrutinib

Expected to end: 01/01/2028

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Studying long-term data for Venetoclax in people who were previously taking the drug on other trials

Expected to end: 01/02/2026

An Open-label, Phase 2 Study of ACP-196 in Subjects With Waldenström Macroglobulinemia

Measuring the safety and efficacy of Acalabrutinib in people with WM

Expected to end: 31/12/2026

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Measuring the safety and efficacy of nemtabrutinib, a type of BTK inhibitor

Expected to end: 19/03/2027

Oxford Pre-cancerous Lymphoproliferative Disorders Study (OxPLoreD)

Looking for markers that might predict disease is progressing

Expected to end: 01/10/2025

Rituximab and Ibrutinib (RI) versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström’s Macroglobulinaemia (RAINBOW)

Is ibrutinib and rituximab a more effective first-line treatment than the current standard first-line treatment for people with WM?

Expected to end: 01/03/2030

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Understanding the dosage and safety of a new type of treatment

Expected to end: 30/08/2027

Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia (CLOVER-WaM)

Measuring the efficacy of a drug called Iopofosine I131 in patients with WM

Expected to end: 22/12/2026

Study to Evaluate CCS1477 in Haematological Malignancies

Finding out more about a new type of targeted treatment

Expected to end: 30/06/2025

Study to Evaluate the Efficacy and Safety of Sonrotoclax in Participants With Waldenström’s Macroglobulinemia

Understanding the safety and efficacy of a new drug that stops a certain type of protein working

Expected to end: 01/09/2028

Study to Evualate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants with B-Cell Malignancies

Assessing the safety and effectiveness of a medication called ABBV-101 in people with certain types of relapsed non-Hodgkin’s lymphomas

Expected to end: 01/03/2031

Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies (ELM-1)

Understanding the best doses for Odronextamb in patients with a type of protein on their B-cells

Expected to end: 30/09/2025